[{"id":"11f51dac-7e1d-49bc-a831-2bb40a26e80c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01701232","created_at":"2021-01-18T07:23:49.499Z","updated_at":"2024-07-02T16:37:16.632Z","phase":"Phase 3","brief_title":"Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT01701232","lead_sponsor":"Biocad","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • AcellBia (rituximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 174","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 01/01/2017","primary_completion_date":" 01/01/2017","study_txt":" Completion: 01/01/2017","study_completion_date":" 01/01/2017","last_update_posted":"2017-11-06"}]